Key result
Atorvastatin trial evaluates 30-day mortality reduction versus no statin in acute aortic dissection.
Why the study?
The effect of statins on the survival of patients with acute aortic dissection has been scarcely investigated, especially in randomized trials.
Does atorvastatin reduce in-hospital mortality at 30 days in patients with acute aortic dissection?
RCT (n=384)
Open-label
Block randomization
No
Does atorvastatin reduce in-hospital mortality at 30 days in patients with acute aortic dissection?
This study protocol outlines a randomized trial to evaluate whether atorvastatin reduces 30-day in-hospital mortality in patients with acute aortic dissection.
Answers are grounded in this paper and cite their sources.
Retrospective data leave atorvastatin's benefit in acute aortic dissection open; the planned RCT will provide first direct evidence.
BACKGROUND: Dyslipidemia and local inflammation at sites of lipid deposition on blood vessel walls have been demonstrated to be risk factors for patients with acute aortic dissection (AAD). Statins have anti-inflammatory and lipid-lowering effects, which suggest that statins may play an important role in the prevention and treatment of AAD. Some retrospective studies show that statins can protect patients with aortic dissection. However, the effect of statins on the survival of AAD patients has been scarcely investigated, especially in randomized trials. In this study, we will perform a randomized clinical trial to understand whether statins can reduce in-hospital mortality of AAD patients. METHODS: A total of 384 subjects diagnosed with AAD in the First Affiliated Hospital of Shantou University Medical College will be recruited. Participants will be randomly divided into an atorvastatin-treated or control group. The primary outcome will be the in-hospital mortality at 30 days. DISCUSSION: This study is designed to verify the efficacy of atorvastatin on reducing in-hospital mortality of patients with AAD. The aim is to provide a new means of improving survival as a complement to conventional drug therapy. TRIAL REGISTRATION: Chinese Clinical Trials Registry ChiCTR1900023515 . Registered on 1 June 2019.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2021) conducted an RCT in Acute aortic dissection (n=384). Atorvastatin vs. No statin therapy was evaluated on In-hospital mortality at 30 days. Atorvastatin 20 mg daily will be evaluated in a randomized clinical trial to determine if it reduces 30-day in-hospital mortality compared to no statin therapy in patients with acute aortic dissection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: